Polyrizon Ltd.(PLRZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PLRZ Polyrizon Ltd.

Market Closed 03-13 16:00:00 EDT

14.30

-0.99

-6.47%

盘后14.30

+0.000.00%

19:46 EDT

High15.26	Low13.15	Vol47.85K
Open15.16	D1 Closing15.29	Amplitude13.80%
Mkt Cap14.90M	Tradable Cap14.25M	Total Shares1.04M
T/O686.48K	T/O Rate4.80%	Tradable Shares996.80K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":14.3,"timestamp":1773432000000,"preClose":15.29,"halted":0,"volume":47853,"hourTrading":{"tag":"盘后","latestPrice":14.3,"preClose":14.3,"latestTime":"19:46 EDT","volume":48,"amount":650.84,"timestamp":1773445570568,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.06474820143884882,"floatShares":996800,"shares":1041700,"eps":-0.71144193,"marketStatus":"Market Closed","change":-0.99,"latestTime":"03-13 16:00:00 EDT","open":15.16,"high":15.26,"low":13.15,"amount":686476.6710165,"amplitude":0.137999,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.71144193,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773648000000},"marketStatusCode":7,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":15.29,"preHourTrading":{"tag":"盘前","latestPrice":15,"preClose":15.16,"latestTime":"09:28 EDT","volume":528,"amount":7885.029504,"timestamp":1773408481061,"change":-0.16,"changeRate":-0.010554,"amplitude":0.00066},"postHourTrading":{"tag":"盘后","latestPrice":14.3,"preClose":14.3,"latestTime":"19:46 EDT","volume":48,"amount":650.84,"timestamp":1773445570568,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.7288257952302852},"requestUrl":"/m/hq/s/PLRZ/wiki","defaultTab":"wiki","newsList":[{"id":"2618937100","title":"Polyrizon Produces GMP Clinical Trial Material Batch With Eurofins CDMO AmatsiAquitaine","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937100","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937100?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:55","pubTimestamp":1773143757,"startTime":"0","endTime":"0","summary":"Polyrizon said it successfully produced a Good Manufacturing Practice  batch of clinical trial material for its lead intranasal product candidate. The batch was manufactured with Eurofins CDMO AmatsiAquitaine and is intended to support a planned U.S. clinical study later this year. Polyrizon said the GMP batch followed two prior development batches that showed batch-to-batch consistency and product stability over time.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL6NFH0m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","LU0314104364.USD","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD","BK4112","LU2210150020.SGD","SG9999014039.USD","BK4588","PLRZ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","NDAQ"],"gpt_icon":0},{"id":"2618937903","title":"Polyrizon Announces Gmp Manufacturing of Clinical Trial Material (Ctm) With Eurofins CDMO Amatsiaquitaine S.a.s for Planned U.S. Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937903?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:55","pubTimestamp":1773143700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA5MXWMW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4139"],"gpt_icon":0},{"id":"2614421330","title":"BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2614421330","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614421330?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:28","pubTimestamp":1772112500,"startTime":"0","endTime":"0","summary":"BUZZ-Polyrizon rises as lab study shows improved nasal delivery for overdose drug** Shares of drug developer Polyrizon PLRZ.O rise 5.2% to $14.25 premarket** Co says its experimental naloxone nasal spray delivered about 95% of the drug to the upper nasal cavity — a region that helps rapid absorption — vs ~80% for a commercial product** PLRZ's naloxone is used to quickly reverse opioid overdoses, per co** Co says less of the drug remained in the lower nasal area, which could reduce drainage and improve consistency** Study was conducted at the University of Parma; co says results support its broader intranasal drug delivery strategy** Shares down over 99% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL4N3ZM1AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2614044222","title":"Polyrizon Reports Study Showing Improved Nasal Deposition for Its Naloxone Formulation Versus Commercial Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2614044222","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614044222?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:12","pubTimestamp":1772111555,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. reported results from a comparative study assessing the regional nasal deposition profile of its intranasal naloxone formulation versus a commercial reference product. Using a validated silicone nasal cast model with quantitative image analysis at the University of Parma’s Biopharmanet-TEC center, Polyrizon’s formulation showed 94.6%  deposition in the nasal vestibule and upper turbinate compared with 79.6%  for the reference product, and 5.4% deposition in the lower turbinate versus 20.4% for the reference. The results have already been presented in the company’s announcement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL13Nxj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","BK4112","LU2210150020.SGD","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","PLRZ","BK4588","SG9999014013.SGD","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2614044216","title":"Polyrizon Announces Successful Study of Its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2614044216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614044216?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:12","pubTimestamp":1772111520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA8NMLLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2612628286","title":"Clearmind Medicine Reports Progress on MEAI as Next-Generation Weight Loss Therapy Market Shifts Beyond GLP-1 Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2612628286","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612628286?lang=en_us&edition=fundamental","pubTime":"2026-02-20 02:05","pubTimestamp":1771524345,"startTime":"0","endTime":"0","summary":"Clearmind Medicine Inc. reported progress related to its proprietary non-hallucinogenic neuroplastogen MEAI , including continued advancement of an FDA-approved Phase I/IIa clinical trial in alcohol use disorder. The company said multiple cohorts have been completed and that trial data readouts will be presented in the future. Clearmind also cited preclinical obesity findings for MEAI published in ACS Pharmacology & Translational Science and noted new patent applications and a collaboration with Polyrizon to develop an intranasal formulation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL8bRMS7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","CMND","BK4007"],"gpt_icon":0},{"id":"2610621072","title":"BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab","url":"https://stock-news.laohu8.com/highlight/detail?id=2610621072","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610621072?lang=en_us&edition=fundamental","pubTime":"2026-02-10 23:41","pubTimestamp":1770738077,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, EcolabEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL6N3Z60ZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","DD","WTW","MCHP","NKTR","WMB","RNG","BK4196","HIMZ","RGNX","WING","LU1815333072.USD","HMYY","LU1032466523.USD","FDX","FTAI","INCY","DGX","IE00BN8TJ469.HKD","FLNC","J","HIMS","UPWK","LU2290526834.HKD","GM","HIMY","LU1670710588.SGD","PSNL","SPOT","WCC","MAR","BDX","ON","LU0545039389.USD","ECL","MAS","PLRZ","DDOG","KO","CCO","HL","HOG","TECX","BK4585","CAT","VST","OSCR","HAS","UAA","ZBH"],"gpt_icon":0},{"id":"2610647780","title":"BUZZ-Drug developer Polyrizon climbs on deal to buy 51% of air ambulance operator","url":"https://stock-news.laohu8.com/highlight/detail?id=2610647780","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610647780?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:35","pubTimestamp":1770726932,"startTime":"0","endTime":"0","summary":"BUZZ-Drug developer Polyrizon climbs on deal to buy 51% of air ambulance operator** Shares of drug developer Polyrizon PLRZ.O rise 10.04% to $14.58 premarket** Co says it signed a nonbinding deal to buy 51% of medical transport services provider Arrow Aviation ** Arrow provides services including air ambulance flights and medical evacuations, using its fleet of private jets** PLRZ says Arrow generated about $19 million in annual unaudited revenue and $3 million in adjusted earnings** Says a third party will transfer a Hawker 800 aircraft valued at $3.5 million to Arrow in exchange for convertible notes of Polyrizon ** Arrow's shareholders will waive the aviation firm's debts in exchange for additional Polyrizon convertible notes – PLRZ** Shares halved in value in 2025  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL4N3Z61A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2610642376","title":"BRIEF-Polyrizon Intends To Secure Controlling Stake In Profitable Private Jet Operator","url":"https://stock-news.laohu8.com/highlight/detail?id=2610642376","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610642376?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:01","pubTimestamp":1770724893,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Intends To Secure Controlling Stake In Profitable Private Jet OperatorFeb 10 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON INTENDS TO SECURE CONTROLLING STAKE IN PROFITABLE PRIVATE JET OP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z60N9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2610664447","title":"Polyrizon Ltd - Signing of Definitive Agreement Expected Within 30 Days of Mou, Subject to Due Diligence","url":"https://stock-news.laohu8.com/highlight/detail?id=2610664447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610664447?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:56","pubTimestamp":1770724609,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z60N9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2610644497","title":"Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator","url":"https://stock-news.laohu8.com/highlight/detail?id=2610644497","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610644497?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:56","pubTimestamp":1770724609,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z60N9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2610457644","title":"Polyrizon to Acquire 51% Stake in Arrow Aviation for $5.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2610457644","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610457644?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:55","pubTimestamp":1770724512,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. has signed a non-binding Memorandum of Understanding with Arrow Aviation Ltd., a global private aviation company, to acquire a 51% stake in Arrow Aviation for approximately $5.8 million . The proposed deal includes ancillary arrangements such as the transfer of a Hawker 800 aircraft, valued at $3.5 million, to Arrow Aviation in exchange for a convertible note issued by Polyrizon. Existing Arrow Aviation shareholders will forgive outstanding shareholder debts in return for additional convertible notes from Polyrizon, allowing Arrow Aviation to be debt-free after the transaction closes. The agreement also outlines mutual options for the remaining 49% of Arrow Aviation’s shares, exercisable after two years based on financial performance metrics, potentially allowing Polyrizon to acquire full ownership. Arrow Aviation reported approximately $19 million in annual unaudited revenues and about $3 million in adjusted EBITDA. Completion of the transaction remains subject to due d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL3wVxfq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","NDAQ","PLRZ","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","BK4112","SG9999014013.SGD","LU0314104364.USD","LU2210149790.SGD","BK4588","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2609151275","title":"BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina","url":"https://stock-news.laohu8.com/highlight/detail?id=2609151275","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609151275?lang=en_us&edition=fundamental","pubTime":"2026-02-07 02:45","pubTimestamp":1770403531,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z20MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVY","VG","HOYY","NWSA","RIOT","AZYY","NVR","EQT","MAXN","MCHP","PIPR","SGP","LEN","CNX","NSC","UAA","FTNT","NEM","MOH","TGTX","NWL","EXE","COTY","PHM","THAR","ROIV","CG","GWW","KBH","PM","CDE","HL","OFRM","PAA","UI","DOCS","BIIB","HUBG","AGMB","MGM","PLRZ"],"gpt_icon":1},{"id":"2609859779","title":"BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison","url":"https://stock-news.laohu8.com/highlight/detail?id=2609859779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609859779?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:56","pubTimestamp":1770393385,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery DennisonEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z20YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVY","HL","THAR","HUBG","ROBN","NEM","ROIV","COTY","DOCS","TGTX","FTNT","BIIB","NWSA","NSC","09399","VG","MAXN","PAA","RIOT","UAA","3LMI.UK","MCHP","07399","PM","PLRZ","09799","CDE","MOH","NWL","CG","UI","GWW","EXE","HODU","OFRM","MGM","AMZD","CNX","EQT","HOYY","AMZZ"],"gpt_icon":1},{"id":"2609962715","title":"BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI","url":"https://stock-news.laohu8.com/highlight/detail?id=2609962715","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609962715?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:30","pubTimestamp":1770384643,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAIFeb 6 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z20V9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","PLRZ","BK4007"],"gpt_icon":0},{"id":"2609596155","title":"BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2609596155","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609596155?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:25","pubTimestamp":1770384335,"startTime":"0","endTime":"0","summary":"BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery** Shares of drug developer Polyrizon PLRZ.O rise 12.6% to $14.00 premarket ** Co says it will develop an intranasal version of Clearmind’s CMND.O experimental MEAI therapy, being studied for addiction-related brain disorders** CNMD's shares were up 20% at $1.7 premarket** CNMD's MEAI is designed to reshape neural pathways without hallucinations; intranasal delivery may help faster absorption and bypass the liver, per co** Co says its gel-like nasal platform aims to keep drugs longer in the nose and improve targeted delivery** PLRZ shares down over 99%, CNMD down ~41% in 2025  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL4N3Z21E3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND","PLRZ"],"gpt_icon":0},{"id":"2609953545","title":"Clearmind Medicine Enters Into Development Agreement to Advance Intranasal Formulation for Its Proprietary Non-Hallucinogenic Neuroplastogen Meai","url":"https://stock-news.laohu8.com/highlight/detail?id=2609953545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609953545?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:55","pubTimestamp":1770382530,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z20V9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","CMND","BK4007"],"gpt_icon":0},{"id":"2609259539","title":"Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2609259539","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609259539?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:55","pubTimestamp":1770382510,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd., a pre-clinical-stage biotechnology company, has entered into a development agreement with Clearmind Medicine Inc., a clinical-stage biopharmaceutical firm. The collaboration focuses on developing a proprietary intranasal formulation of MEAI, Clearmind's next-generation, non-hallucinogenic neuroplastogen drug candidate aimed at treating addiction-related and other central nervous system conditions. Polyrizon will leverage its advanced intranasal delivery platform to enhance the clinical development of MEAI, offering targeted delivery and potentially faster absorption. The partnership is expected to support Clearmind's future clinical programs and highlights Polyrizon's expertise in specialized intranasal drug delivery solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL95mddZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","NDAQ","LU2095319765.USD","PLRZ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","SG9999014039.USD","LU2210149790.SGD","BK4585","LU2210150020.SGD","SG9999014013.SGD","BK4112","SG9999014021.USD","IE00BKPKM429.USD","BK4007","CMND"],"gpt_icon":0},{"id":"2609595351","title":"Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2609595351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609595351?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:55","pubTimestamp":1770382500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA32DWG8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007","PLRZ"],"gpt_icon":0},{"id":"2608696793","title":"Polyrizon intends to acquire 51% stake in Arrow Aviation for NIS 18M","url":"https://stock-news.laohu8.com/highlight/detail?id=2608696793","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608696793?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:15","pubTimestamp":1770207320,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the signing of a non-binding Memorandum of Understanding with Arrow Aviation, a global private aviation company. Under t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-intends-to-acquire-51-stake-in-arrow-aviation-for-nis-18m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-intends-to-acquire-51-stake-in-arrow-aviation-for-nis-18m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ","AROW","BK4211"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.polyrizon-biotech.com","stockEarnings":[{"period":"1week","weight":0.0908},{"period":"1month","weight":0.1128},{"period":"3month","weight":0.134},{"period":"6month","weight":0.9861},{"period":"1year","weight":-0.986},{"period":"ytd","weight":0.6843}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Polyrizon Ltd.","nameEN":"Polyrizon Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Polyrizon Ltd.(PLRZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Polyrizon Ltd.(PLRZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Polyrizon Ltd.,PLRZ,Polyrizon Ltd.股票,Polyrizon Ltd.股票老虎,Polyrizon Ltd.股票老虎国际,Polyrizon Ltd.行情,Polyrizon Ltd.股票行情,Polyrizon Ltd.股价,Polyrizon Ltd.股市,Polyrizon Ltd.股票价格,Polyrizon Ltd.股票交易,Polyrizon Ltd.股票购买,Polyrizon Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Polyrizon Ltd.(PLRZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Polyrizon Ltd.(PLRZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction